Core Viewpoint - Bone Biologics Corporation has announced a public offering of 781,251 shares of common stock at a price of $2.56 per share, along with warrants to purchase an equal number of shares, aiming to raise approximately $2.0 million for clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 781,251 shares of common stock and warrants, priced at $2.56 per share, with warrants having an exercise price of $2.43, exercisable immediately and expiring in five years [1][2]. - The expected gross proceeds from the offering are approximately $2.0 million before deducting fees and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, maintain and extend the patent portfolio, and for working capital and other general corporate purposes [2]. Group 3: Company Background - Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing a bone graft substitute product based on preclinical research of the Nell-1 protein [5].

Core Viewpoint - Bone Biologics Corporation is advancing its product candidate NB1 into human clinical testing for spinal fusion, with three hospital sites engaged for a pilot clinical trial evaluating its safety and effectiveness in treating degenerative disc disease [1][2]. Company Overview - Bone Biologics Corporation focuses on regenerative medicine for bone, particularly through its NB1 bone graft device, which is designed for spinal fusion procedures and has potential applications in trauma and osteoporosis [5]. Product Details - NB1 is a recombinant human protein (rhNELL-1) combined with demineralized bone matrix, aimed at enhancing bone regeneration and healing, especially in challenging cases [3]. - The mechanism of action for rhNELL-1 involves receptor binding and intracellular signaling to promote osteogenic gene expression and bone formation [3]. Market Opportunity - The global market for bone graft substitutes in spine fusion is estimated at $3 billion annually, with additional long-term opportunities in the $11 billion market for osteoporosis treatment and the $8 billion market for trauma treatment [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Emerging growth company ☐ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 42-1743430 (State or other jurisdiction of incorporation or formation) (I.R.S. employer identification number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 42-1743430 (State or other jurisdiction of incorporation or formation) (I.R.S. employer identification number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 42-1743430 (State or other jurisdiction of incorporation or formation) (I.R.S. employer identification number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Stock Market LLC Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Stock Market LLC Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Stock Market LLC FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo ...